|Day Low/High||15.25 / 15.59|
|52 Wk Low/High||10.51 / 21.00|
Ixmyelocel-T is the First Therapy to Receive the RMAT Designation for the Treatment of a Serious Cardiovascular Disease
Accomplished Industry Veteran Brings Extensive Quality and Regulatory Affairs Experience in Cell and Gene Therapies and Medical Devices
Investors in Vericel Corp saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VCEL options chain for the new March 17th contracts and identified the following call contract of particular interest.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.